Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy
- Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug development
- Appointments strengthen Rewind’s clinical experience as its GPR17 remyelination therapy advances toward clinical trials
Leuven, Belgium – 18 June 2025 – Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, today announced the appointment of four internationally renowned neurology innovators: Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan to its Scientific Advisory Board (SAB). These appointments come at a critical inflection point for Rewind, as it accelerates the development of its first-in-class GPR17 modulator, a novel therapeutic candidate targeting remyelination in neurological disorders, such as MS.
